Yeztugo showed promising results in clinical trials. One study involving women in Africa reported 100% efficacy, with zero ...

The US Food and Drug Administration (FDA) approved Yeztugo, a long-awaited semi-annual injectable treatment for the prevention of HIV, developed by Gilead Sciences. The approval of Yeztugo marks a ...

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect Efficacy With 99.9% of Pa ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

June 19, 2025 – The FDA has approved the first twice-yearly shot to reduce the risk of HIV infections.

While a vaccine to prevent HIV still is needed, some experts say the shot - a drug called lenacapvir - could be the next best ...

In two recent studies, this new shot reportedly nearly eliminated new infections in people at substantial risk of HIV.

WASHINGTON - The Food and Drug Administration on Wednesday approved Gilead Sciences' lenacapavir, a twice-yearly injection for preventing HIV infection in adults and adolescents. The drug, part of a ...

Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, though a licensing agreement remains a possibility. The asking price has ...

Sanofi India denies reports of Lantus sale, calls media reports ‘unfounded’ The French pharmaceutical major has reportedly slashed the asking price for Lantus from an initial Rs 3,000 crore to ...